| Literature DB >> 28962240 |
Pérez Tuñón Jorge Guillermo1, Pérez Hernández Juan Carlos2, Bautista Albiter Mayré Ivonne2, Terán Flores Herminio2, Ramírez Pérez Rubén3.
Abstract
BACKGROUND: Reported cases of potassium overdoses have shown that this condition could generate several morbidities, mainly related to cardiac dysrhythmias even with fatal outcomes in some cases. Potassium salts in extended release tablets could form pharmacobezoars if a large amount is ingested. In relation to the above, when the patient has a pharmacobezoar, clinical findings may be delayed and may persist. The techniques available for removal of a pharmacobezoar are whole bowel irrigation (WBI), endoscopy or in some surgery [1]. Endoscopy as a decontamination method has shown promising results. CASE REPORT: A 42 year old woman, who intentionally ingested 100 tablets of extended release potassium chloride, 50 mg of clonazepam and an undisclosed amount of ethanol, presented with metabolic acidosis, hyperlactatemia and sinus tachycardia 2 h after ingestion. Gastric lavage and activated charcoal were applied initially, specific measures were not necessary. However, a transcutaneous pacemaker was placed. Because of her background, we considered a pharmacobezoar and an endoscopy were performed to remove 99 tablets of potassium that were isolated or forming concretions. DISCUSSION: The readily available techniques to remove a pharmacobezoar are whole bowel irrigation (WBI) and endoscopy; nevertheless there is not a consensus about their relative merits. Our patient was treated by endoscopy because we found on the X-ray a conglomerate of radiopaque images suggesting a pharmacobezoar. In this case we did not have any adverse effect.Entities:
Keywords: Endoscopy; Extended release potassium salts; Pharmacobezoar
Year: 2014 PMID: 28962240 PMCID: PMC5598358 DOI: 10.1016/j.toxrep.2014.04.002
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Fig. 1Abdominal radiography with multiple radioopacities in the stomach (red arrow).
Fig. 2Endoscopic removal of the tablets.
Fig. 3Removed tablets.
Case development.
| Time | Serumpotassium, blood gas | Therapeutics |
|---|---|---|
| Arrival | K 3.9 mmol/L | Parenteral solutions |
| pH 7.25, HCO3 17, Lact 4.9 mmol/L | Not Anti hyperkalemic measures. Transcutaneouspacemaker | |
| Endoscopy | ||
| 5 h | K 3.5 mmol/L | Not Anti hyperkalemicmeasures |
| pH 7.39, HCO3 18.3, Lact 0.6 mmol/L | ||
| 8 h | K 3.4 mmol/L | Not Anti hyperkalemicmeasures |
| 18 h | K 4.3 mmol/L | Not Anti hyperkalemic measures. Transcutaneous pacemaker was removed |
Reported cases.
| Report | Patient | Time (intake) | Extended release KCl | Findings | Serum K | Therapy |
|---|---|---|---|---|---|---|
| Charles et al. (1978) | 32, F | 18 h | 47 tabs (8 mmol) | Diarrhea, death | 10.8 mmol/l | 0 |
| Illingworth (1980) | 36, M | 5 h | Unknown | Wide complex tachycardia (125×) | 8.9 mml/l | 5, 6, 7, 9, 10 |
| Colledge et al. (1988) | 24, F | 2 h | 100 tabs | Hyperacute T waves, sinus tachycardia 110×. Ventricular tachycardia | 6.4 mmol/l | 1, 5, 6, 7 |
| Steedman (1988) | 27, F | 12 h | 60 tabs (8 mmol) | 1st degree AV blockade, QRS widening and hyperacute T waves | 9.1 mmol/l | 5, 6, 7, 9,12 |
| Peeters et al. (1998) | 62, F | ? | 300 tabs (2.4 mmol) | Abdominal distension. One month later gastric necrosis | Not report | 3 |
| 58, M | 5 h | 20 tabs of extended release KCl (630 mg). Bendoflurazide and phenylbutazone | Left ventricular heart failure | 8 mmol/l | 1, 6, 9, 10 | |
| 26, M | 3.5 h | 10 tabsdextropropoxyphene – acetaminophen | Unaltered EKG. Nausea and vomiting, Asystole, death in gastric lavage | 9.3 mmol/l | 1 | |
| 2 months | 24 h | 5 tabs (8 mmol) | Death | 10.1 mmol/l | 0 | |
| Whitaker et al. (2000) | 30 months | 30 min | 32 tabs | Tachycardia (155×) 1st degree AV blockade. Hyperacute T waves | 9.2 mmol/l | 2, 5, 6, 9, 10 |
| Su (2001) | 50, F | 1 h | 100 tabs (10 mEq) | Hyperacute T waves | 8.2 mmol/l | 1, 2, 4, 5, 6, 7, 9, 13 |
| 17 a, M | 10 h | 20–30 tabs (10 mEq) | Tachycardia, nausea, vomiting and diarrhea | 5.5 mmol/l | 2 | |
| Wan (2007) | 86, M | Chronic | 70 tabs (8 mmol) | Asthenia and adinamia | 6.8 mmol/l | 2, 5, 6, 7 |
| Gunja (2011) | 42, F | 90 min | 40 tabs (8 mmol) | Tachycardia (100×) | 5.5 mmol/l | 6, 2 |
| 42, F | 5 h | 100 tab (8 mmol) | Tachycardia (124×) | 8.5 mmol/l | 5, 6, 7, 4 | |
| 6, M | 2 h | 10–20 tab (8 mmol) | Plane T waves | 7.6 mmol/l | 4, 5, 6, 7, 8. | |
| Saxena (1988) | 46, F | 1 h | 100 tab (8 mmol) | Cardiac arrest | 9.6 mmol/l | 1, 5, 6, 7, 9, 11, 14. |
| Briggs Albert et al. (2013) | 44, F | 75 min | 30 tab (20 mEq) | Mildly peaked T waves | 7.3 mmol/L | 2, 3, 5, 6, 7, 8. |
| Pérez et al. (2013) | 42, F | 2 h | 100 tab (10 mEq) | Metabolic acidosis, hyperlactatemia and sinus tachycardia with normal T waves | 3.9 mmol/L | 1, 3, 11 |
1: gastric lavage; 2: whole bowel irrigation; 3: endoscopy; 4: hemodialysis; 5: calcium; 6: insulin/glucose; 7: sodium bicarbonate; 8: β-2 agonist; 9: ion exchange resin; 10: furosemide; 11: activated charcoal; 12: mannitol; 13: cardiac pacemaker and 14: advanced cardiac resuscitation.